Elucidation of regulation mechanism of sphingolipid biosynthesis and degradation based on protein structure.

基于蛋白质结构阐明鞘脂生物合成和降解的调控机制。

基本信息

  • 批准号:
    18570114
  • 负责人:
  • 金额:
    $ 2.63万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2006
  • 资助国家:
    日本
  • 起止时间:
    2006 至 2007
  • 项目状态:
    已结题

项目摘要

Serine palmitoyltransferase (SPT) catalyzes the first and rate-limiting step reaction of the sphingolipid biosynthesis. The change of the SPT activity influences directly the total amount and the kind of the cellar sphingolipids. Therefore, the elucidation of the regulation mechanism of SPT is very important. (1) We cloned the SPT genes of the various kinds of the sphingolipid-content bacteria, constructed the overexpression system of SPT in E. coli, and established the purification method of each recombinant SPT. (2) We succeeded in synthesis of a non-reactive analogue of palmitoyl-CoA, S-(2-oxoheptadecyl)-CoA. Using the purified recombinant SPT, the reaction of SPT with L-serine and S-(2-oxoheptadecyl)-CoA was examined in detail. By the addition of L-serin to SPT, the external aldimine intermediate is formed via the Michaelis complex. When S-(2-oxoheptadecyl)-CoA was added to this SPT-L-serine binary complex, it was not converted to the final product 3-ketodihydrosphingosine, but the … More new absorption peak of the quinonoid intermediate was detected. The kinetic analysis of time resolved spectra of this ternary complex showed that the binding of the S-(2-oxoheptadecyl)-CoA to the SPT induces the formation. And accumulation of the quinonoid intermediate and the SPT reaction is in equilibrium between the quinonid intermediate and the former external aldimine intermediate. (3) The rate of the α-deprotonation of L-serin by SPT, that corresponds to the rate of the quinonoid formation, was examined by NMR. NMR studies showed that the hydrogen-deuterium exchange at Ca of L-serine is very slow in the SPT-L-serine external aldimine complex, but the rate is 100-fold increased by the addition of S-(2-oxoheptadecyl)-CoA, showing a remarkable substrate synergism in SPT. (4) We succeeded in crystallization of SPT. The structure of SPT・L-serine external aldimine complex had been determined. Based on the crystallographic data, the discussion about the role of the conserved amino acid residues in the SPT catalysis became possible. Less
丝氨酸棕榈酰转移酶(SPT)催化了鞘脂生物合成的第一个和限制的步骤反应。 SPT活性的变化直接影响了地窖鞘脂的总量和种类。因此,阐明SPT的调节机制非常重要。 (1)我们克隆了各种鞘脂含量细菌的SPT基因,构建了大肠杆菌中SPT的过表达系统,并建立了每种(2)的纯化方法,我们成功地合成了棕榈酸-COA的非反应类似物的类似物,palmitoyl-CoA,s-(2- oxoxoheptadecylecyl)-CoA。使用纯化的重组SPT,详细检查了SPT与L链氨酸和S-(2-氧HopTadecyl)-COA的反应。通过向SPT添加L塞林,外部醛氨酸中间体是通过Michaelis Complex形成的。当将S-(2-氧二甲苯基)-COA添加到该SPT-L-丝氨酸二元复合物中时,它没有转化为最终产物3-酮二氢磷酸酯,但是……检测到奎诺酮中间体的更多新吸收峰。该三元复合物的时间解析光谱的动力学分析表明,s-(2-氧二甲苯基)-COA与SPT的结合会影响形成。奎诺酮中间体和SPT反应的积累在奎诺酮中间体和以前的外部醛氨酸中间体之间。 (3)通过NMR检查了与奎诺尼形成速率相对应的SPT的L-塞林的α-二苯甲酸的速率。 NMR的研究表明,在SPT-L-丝氨酸外部醛氨酸复合物中,L链CA的氢 - 居民交换非常慢,但是通过添加S-(2-氧霍普二烷基)-COA,速率提高了100倍,显示了SPT中的显着底物协同作用。 (4)我们成功地结晶了SPT。已经确定了SPT ・ l-serine外部醛酸复合物。基于晶体学数据,有关配置氨基酸在SPT催化中保留的作用的讨论变得可能是可能的。较少的

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
5-アミノレブリン酸合成酵素の大量調製と諸特性の解析,結晶化
5-氨基乙酰丙酸合酶的大规模制备、各种性质分析及结晶
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    宮原 郁子;長見 篤;生城 浩子;神谷 信夫;林 秀行
  • 通讯作者:
    林 秀行
Structural Biology of Sphingolipid Synthesis.in Sphingolipid Biology(Hirabayashi, Y., Igarashi, Y., & Merrill, A., Eds.)
鞘脂生物学中鞘脂合成的结构生物学(Hirabayashi, Y., Igarashi, Y.,
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Ikushiro H;Okamoto A;Hayashi H
  • 通讯作者:
    Hayashi H
Structural Biology of Sphingolipid Synthesis.
鞘脂合成的结构生物学。
Analysis of Quinonoid Intermediate Formation of Serine Palmitoyltransferase Using Substrate Analogue
使用底物类似物分析丝氨酸棕榈酰转移酶的醌类中间体形成
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Ikushiro H;Fujii S;Hayashi H.
  • 通讯作者:
    Hayashi H.
Study on serine palmitoyltransferase, the rate limiting enzyme of sphingolipid biosynthesis.
鞘脂生物合成限速酶丝氨酸棕榈酰转移酶的研究。
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    生城 浩子;長見 篤;白岩 有桂;竹野内 政紀;宮原 郁子;神谷 信夫;林 秀行;生城 浩子;Ikushiro H
  • 通讯作者:
    Ikushiro H
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

IKUSHIRO Hiroko其他文献

IKUSHIRO Hiroko的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('IKUSHIRO Hiroko', 18)}}的其他基金

Studies on the molecular mechanism of sphingolipid metabolism based on the crystal structure of the enzymes
基于酶晶体结构研究鞘脂代谢的分子机制
  • 批准号:
    21570149
  • 财政年份:
    2009
  • 资助金额:
    $ 2.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似国自然基金

相似海外基金

Atypical sphingolipids in alcoholic liver disease
酒精性肝病中的非典型鞘脂
  • 批准号:
    10453295
  • 财政年份:
    2023
  • 资助金额:
    $ 2.63万
  • 项目类别:
Ceramides as Novel Mediators of Tubular Metabolic Dysfunction Driving Kidney Injury
神经酰胺作为肾小管代谢功能障碍驱动肾损伤的新型调节剂
  • 批准号:
    10677394
  • 财政年份:
    2023
  • 资助金额:
    $ 2.63万
  • 项目类别:
Targeting the detoxification function of the enzyme KDSR for cancer therapy
针对癌症治疗中 KDSR 酶的解毒功能
  • 批准号:
    10595401
  • 财政年份:
    2023
  • 资助金额:
    $ 2.63万
  • 项目类别:
Identification of potential therapeutic lead compounds targeting serine-palmitoyltransferase
鉴定针对丝氨酸棕榈酰转移酶的潜在治疗先导化合物
  • 批准号:
    23K13858
  • 财政年份:
    2023
  • 资助金额:
    $ 2.63万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ceramides as Novel Mediators of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency-Induced Heart Failure.
神经酰胺作为极长链酰基辅酶A脱氢酶缺乏引起的心力衰竭的新型介体。
  • 批准号:
    10747561
  • 财政年份:
    2023
  • 资助金额:
    $ 2.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了